Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Antidepressant Cymbalta: Shionogi
February 1, 2010
- Anti-Flu Agent Rapiacta Included in NHI Price List
February 1, 2010
- Greater Importance Put on Surgery in Insurance Coverage
February 1, 2010
- Xalacom for Glaucoma: Pfizer
February 1, 2010
- Korosho to Ask Companies to Comment on the Need for Listed Unapproved Drugs
February 1, 2010
- Cymbalta to Drive Shionogi's Business in Mid-Term: Ms Sawada
February 1, 2010
- Sugammadex for Reversal of Neuromuscular Blockade: Schering-Plough
February 1, 2010
- New Premium to Allow Chuikyo to Interfere with Company Management : Prof. Tsutsumi
February 1, 2010
- Takeda to More Actively Develop Business in Emerging Markets: President Hasegawa
February 1, 2010
- Anti-Emetic Aloxi: Taiho
February 1, 2010
- New Premium to Trouble Wholesalers Again
January 25, 2010
- Include Prevnar in Periodic Immunization Programs ASAP: Dr Wada
January 25, 2010
- Rate of New Premium for New Drug Development Will Be 5.10%
January 25, 2010
- Eisai to Apply for Eribulin in Japan, the US and Europe in March
January 25, 2010
- 61% of Drug Companies Welcome New Pricing System: Questionnaire
January 25, 2010
- MK-8669 Enters PII in Japan: Banyu
January 25, 2010
- Panel of Experts on Unapproved Drugs/Indications to Be Inaugurated
January 25, 2010
- MBL, Osaka Univ. Isolate Fully-Human Flu Virus MAB
January 25, 2010
- Companies Should Be Encouraged to Participate in New Growth Strategy: Mr Nagatsuma
January 25, 2010
- Tasigna Shown to Be Superior to Glivec for CML: Novartis
January 25, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…